1921
Volume 83, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Antifolate resistance in is caused by point mutations in genes encoding dihydrofolate reductase () and dihydropteroate synthase (). In this study, we used direct sequencing to survey and mutations in 122 clinical isolates from a central and a southern province of China. For , 36.9% were wild-type, whereas mutations were detected at four codons (57, 58, 61, and 117). The S117N/T mutation was the most prevalent (48.4%), followed by the T61M mutation (18.9%). Six mutant alleles were found, ranging from 37.7% to 0.8%. The dramatically different allele frequencies between the two populations might be caused by different drug histories or intrinsic difference between temperate and subtropical strains. In contrast, except polymorphisms within a repeat region, no resistance-conferring mutations were detected in . Our result suggests that populations in China may be relatively susceptible to sulfadoxine-pyrimethamine.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.10-0259
2010-12-06
2017-11-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/6/1206.html?itemId=/content/journals/10.4269/ajtmh.2010.10-0259&mimeType=html&fmt=ahah

References

  1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, , 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 7987.
  2. Anstey NM, Russell B, Yeo TW, Price RN, , 2009. The pathophysiology of vivax malaria. Trends Parasitol 25: 220227.[Crossref]
  3. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA, , 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555566.[Crossref]
  4. Sleigh AC, Liu XL, Jackson S, Li P, Shang LY, , 1998. Resurgence of vivax malaria in Henan Province, China. Bull World Health Organ 76: 265270.
  5. Xu BL, Su YP, Shang LY, Zhang HW, , 2006. Malaria control in Henan Province, People's Republic of China. Am J Trop Med Hyg 74: 564567.
  6. Zhang W, Wang L, Fang L, Ma J, Xu Y, Jiang J, Hui F, Wang J, Liang S, Yang H, Cao W, , 2008. Spatial analysis of malaria in Anhui province, China. Malar J 7: 206.[Crossref]
  7. Zhou SS, Wang Y, Tang LH, , 2007. Malaria situation in the People's Republic of China in 2006. Chin J Parasitol Parasitic Dis 25: 439441.
  8. Baird JK, , 2004. Chloroquine resistance in Plasmodium vivax . Antimicrob Agents Chemother 48: 40754083.[Crossref]
  9. Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S, , 1979. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 73: 1517.[Crossref]
  10. Young MD, Burgess RW, , 1959. Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ 20: 2736.
  11. Mayxay M, Pukrittayakamee S, Newton PN, White NJ, , 2004. Mixed-species malaria infections in humans. Trends Parasitol 20: 233240.[Crossref]
  12. Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ, , 2003. A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites. Mol Biol Evol 20: 15261536.[Crossref]
  13. Pearce RJ, Pota H, Evehe MS, Ba el H, Mombo-Ngoma G, Malisa AL, Ord R, Inojosa W, Matondo A, Diallo DA, Mbacham W, van den Broek IV, Swarthout TD, Getachew A, Dejene S, Grobusch MP, Njie F, Dunyo S, Kweku M, Owusu-Agyei S, Chandramohan D, Bonnet M, Guthmann JP, Clarke S, Barnes KI, Streat E, Katokele ST, Uusiku P, Agboghoroma CO, Elegba OY, Cisse B, A-Elbasit IE, Giha HA, Kachur SP, Lynch C, Rwakimari JB, Chanda P, Hawela M, Sharp B, Naidoo I, Roper C, , 2009. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med 6: e1000055.[Crossref]
  14. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, , 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17: 582588.[Crossref]
  15. Gregson A, Plowe CV, , 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 57: 117145.[Crossref]
  16. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH, , 2007. Antifolates can have a role in the treatment of Plasmodium vivax . Trends Parasitol 23: 213222.[Crossref]
  17. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G, , 2003. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 47: 15141521.[Crossref]
  18. Hastings MD, Maguire JD, Bangs MJ, Zimmerman PA, Reeder JC, Baird JK, Sibley CH, , 2005. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob Agents Chemother 49: 733740.[Crossref]
  19. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, , 2002. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 46: 39473953.[Crossref]
  20. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh le N, Maguire J, Bell D, O'Neil MT, Cheng Q, , 2006. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am J Trop Med Hyg 75: 617621.
  21. Kongsaeree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchompoo B, Walkinshaw MD, Yuthavong Y, , 2005. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 102: 1304613051.[Crossref]
  22. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK, , 2004. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis 189: 744750.[Crossref]
  23. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G, , 2001. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother 45: 31223127.[Crossref]
  24. Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q, , 2004. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother 48: 22142222.[Crossref]
  25. Imwong M, Pukrittayakamee S, Cheng Q, Moore C, Looareesuwan S, Snounou G, White NJ, Day NP, , 2005. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob Agents Chemother 49: 43934395.[Crossref]
  26. Menegon M, Majori G, Severini C, , 2006. Genetic variations of the Plasmodium vivax dihydropteroate synthase gene. Acta Trop 98: 196199.[Crossref]
  27. Rungsihirunrat K, Sibley CH, Mungthin M, Na-Bangchang K, , 2008. Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand. Am J Trop Med Hyg 78: 462467.
  28. Kaur S, Prajapati SK, Kalyanaraman K, Mohmmed A, Joshi H, Chauhan VS, , 2006. Plasmodium vivax dihydrofolate reductase point mutations from the Indian subcontinent. Acta Trop 97: 174180.[Crossref]
  29. Barnadas C, Musset L, Legrand E, Tichit M, Briolant S, Fusai T, Rogier C, Bouchier C, Picot S, Menard D, , 2009. High prevalence and fixation of Plasmodium vivax dhfr/dhps mutations related to sulfadoxine/pyrimethamine resistance in French Guiana. Am J Trop Med Hyg 81: 1922.
  30. Schousboe ML, Rajakaruna RS, Salanti A, Hapuarachchi HC, Galappaththy GN, Bygbjerg IC, Amerasinghe PH, Konradsen F, Alifrangis M, , 2007. Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka. Malar J 6: 28.[Crossref]
  31. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, Maestre A, O'Neil MT, Cheng Q, Joshi H, Na-Bangchang K, Sibley CH, , 2008. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Malar J 7: 72.[Crossref]
  32. Hawkins VN, Suzuki SM, Rungsihirunrat K, Hapuarachchi HC, Maestre A, Na-Bangchang K, Sibley CH, , 2009. Assessment of the origins and spread of putative resistance-conferring mutations in Plasmodium vivax dihydropteroate synthase. Am J Trop Med Hyg 81: 348355.
  33. Brega S, de Monbrison F, Severini C, Udomsangpetch R, Sutanto I, Ruckert P, Peyron F, Picot S, , 2004. Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolates. Antimicrob Agents Chemother 48: 25812587.[Crossref]
  34. Na BK, Lee HW, Moon SU, In TS, Lin K, Maung M, Chung GT, Lee JK, Kim TS, Kong Y, , 2005. Genetic variations of the dihydrofolate reductase gene of Plasmodium vivax in Mandalay Division, Myanmar. Parasitol Res 96: 321325.[Crossref]
  35. Thompson JD, Higgins DG, Gibson TJ, , 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 46734680.[Crossref]
  36. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK, , 1998. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol 92: 265273.[Crossref]
  37. Hastings MD, Sibley CH, , 2002. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax . Proc Natl Acad Sci USA 99: 1313713141.[Crossref]
  38. Rungsihirunrat K, Na-Bangchang K, Hawkins VN, Mungthin M, Sibley CH, , 2007. Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. Am J Trop Med Hyg 76: 10571065.
  39. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ, , 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 16801685.[Crossref]
  40. Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G, , 2009. Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan. Am J Trop Med Hyg 81: 525528.
  41. Zakeri S, Motmaen SR, Afsharpad M, Djadid ND, , 2009. Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar J 8: 20.[Crossref]
  42. Zhou Z, , ed., 1991. Malaria Control and Research in China. Beijing: People's Hygiene Press.
  43. Shen J, Hu X, , 1978. Comparison of the antimalarial effect of long-term pyrimethamine prophylaxis versus change to “antimalarial drug combination no. 3”. Railway Med J 6: 9091.
  44. Su BY, Huang HM, , 1982. Observation on the preventive effect of eight-week pyrimethamine and primaquine treatment on vivax malaria. Guangxi Med J 4: 1213.
  45. Chen JS, Zhang KR, Geng ZW, , 1977. Observation on clinical efficacy of pyrimethamine on Plasmodium vivax in Kaifeng District. Henan J Prev Med 9: 5156.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.10-0259
Loading
/content/journals/10.4269/ajtmh.2010.10-0259
Loading

Data & Media loading...

  • Received : 05 May 2010
  • Accepted : 04 Aug 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error